Most Read Articles
05 Nov 2019
Low total cholesterol levels appear to carry increased major adverse cardiovascular events (MACE) hazard in older men without ischaemic heart disease (IHD) and not receiving statin therapy but not to those on statins, according to data from the CHAMP (Concord Health and Ageing in Men Project) cohort.
2 days ago
Better sleep appears to weaken pain and fatigue in older, community-dwelling adults with hip or knee osteoarthritis (OA), reports a recent study.
6 days ago
Maribavir 400 mg twice daily appears to have comparable efficacy to valganciclovir at clearing cytomegalovirus viraemia in transplant recipients, a study has found.
5 days ago
Individuals with and without gout appear to have a similar risk of developing colorectal cancer, suggesting that gout does not contribute to a risk increase, a study has found.

Direct-acting antiviral therapy prolongs survival in HCV-infected HCC patients

21 Oct 2019

Use of direct-acting antivirals (DAAs) to treat hepatitis C virus (HCV) in hepatocellular carcinoma (HCC) patients with documented response to therapy appears to yield a significant reduction in mortality, as shown in a recent study.

The retrospective study included 797 patients with HCV-related HCC, among whom 383 (48.1 percent) received DAA therapy. All patients achieved a complete response to resection, local ablation, transarterial chemo- or radioembolization, or radiation therapy.

There were 43 deaths that occurred during 941 person-years of follow-up in the DAA group in comparison with 103 deaths during 526.6 person-years of follow-up in the nontreated group (crude rate ratio, 0.23, 95 percent CI, 0.16–0.33).

Inverse probability-weighted analyses revealed DAA therapy to be associated with a significant decrease in the risk of death (hazard ratio [HR], 0.54, 95 percent CI, 0.33–0.90). This protective association differed by sustained virologic response (SVR) to DAA therapy, such that mortality risk was reduced in patients who achieved SVR (HR, 0.29, 0.18–0.47) but not in those without SVR (HR, 1.13, 0.55–2.33).

Median time from HCC complete response to DAA initiation was 7.7 months, with 20.2 percent of participants treated within 3 months, 21.5 percent between 3 and 6 months, 25.5 percent between 6 and 12 months, and 32.9 percent >12 months after HCC complete response. A total of 79.4 percent of DAA-treated patients achieved SVR, while 11.5 percent had treatment-failure and 9.1 percent had no documented assessment of SVR.

The present data suggest that HCV-infected patients with a history of HCC may benefit from DAA therapies, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
05 Nov 2019
Low total cholesterol levels appear to carry increased major adverse cardiovascular events (MACE) hazard in older men without ischaemic heart disease (IHD) and not receiving statin therapy but not to those on statins, according to data from the CHAMP (Concord Health and Ageing in Men Project) cohort.
2 days ago
Better sleep appears to weaken pain and fatigue in older, community-dwelling adults with hip or knee osteoarthritis (OA), reports a recent study.
6 days ago
Maribavir 400 mg twice daily appears to have comparable efficacy to valganciclovir at clearing cytomegalovirus viraemia in transplant recipients, a study has found.
5 days ago
Individuals with and without gout appear to have a similar risk of developing colorectal cancer, suggesting that gout does not contribute to a risk increase, a study has found.